Fig. 1From: Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesha adverse drug events in patients (HD group/case) treated with high dose of baricitinib (N = 122), b adverse drug events in patients (UD group/control) treated with usual dose of baricitinib (N = 116)Back to article page